cystic fibrosis

News

New cystic fibrosis triple from Vertex backed for NHS use

Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.

News

Trial of Boehringer's cystic fibrosis gene therapy imminent

Boehringer's cystic fibrosis gene therapy is poised to start clinical testing, hoping to offer a one-shot alternative to costly CFTR modulator drugs.

News

Share in cystic fibrosis firm Sionna rise sharply after IPO

Sionna has closed its IPO, raising $191m for cystic fibrosis candidates that it thinks could be more effective than rivals from Vertex.

News

Wales and NI follow England in backing Vertex CF therapies

Three of the four UK nations have agreed a long-term deal with Vertex Pharma for reimbursement of its cystic fibrosis therapies, ensuring permanent access to the drugs for eligible patients

News

Vertex’s chief executive Reshma Kewalramani

Vertex seeks swift review of new CF triple after ph3 readout

Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit

R&D